Oxford BioMedica (OXBDF)
(Delayed Data from OTC)
$5.02 USD
+0.48 (10.55%)
Updated Sep 24, 2024 11:35 AM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Oxford BioMedica [OXBDF]
Reports for Purchase
Showing records 1 - 20 ( 76 total )
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
1H23 Results; Further One-Stop Shopping Moves as Leading Gene Therapy CDMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
2022 Results; Finalizing Transition to Leading Vector CDMO in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Terminating coverage on Biophrama Credit (BPCR), Oxford Biomedica (OXB), Applied Graphene Materials (AGM), Gresham House (GHE) and S Immo (SPI)
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
1H22 Results; If You Build It, They Will Come; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
LentiStable and LentiVector Platforms Keep Grabbing Partners; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
COVID vaccine and Kymriah news encouraging
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
AstraZeneca Continues to Step Up; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
OXB Sets Foot in the U.S With a New AAV Manufacturing and Innovation Business
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
New Year and Deal Flow Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Freedom to Explore New CAR-T Opportunities Unlocked; Novartis Renewed and New Partner Delivered
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Boehringer Ingelheim Exercises Cystic Fibrosis Option in Nice Step Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
1H21 Results; Cranking on All Pistons and a Nice Strategic Investment; Target Increased to #24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Driving innovation in a thriving CGT industry
Provider: Edison Investment Research Limited
Analyst: JANA S
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Extension of AZD1222 CDMO Agreement Provides Welcome Revenue Stream into Near Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
2020 Results; They''ve Built It; People Are Coming
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
Axovant Shines Spotlight on AXO-Lenti-PD Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
It''s a Beautiful SUNRISE Today; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oxford BioMedica
Industry: Medical - Biomedical and Genetics
1H20 Results; Engine Continues to Rev Higher, and It''s Purring
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J